Mutational heterogeneity in genes causative of dominantly inherited disorders represents a significant barrier for development of therapies directed towards correction of the primary genetic defect. To circumvent the mutational heterogeneity present in rhodopsin-(RHO-) linked autosomal dominant Retinitis Pigmentosa (adRP), a strategy involving suppression and replacement of RHO has been adopted. RNA interference-(RNAi-) mediated suppression of RHO has been explored as has the generation of an RNAi-resistant replacement gene using the degeneracy of the genetic code. Additionally, the functional equivalence of codon-modified replacement genes has been demonstrated in a transgenic animal (RHO-M). Suppression and replacement, while exemplified by adRP, may also be relevant to many other dominantly inherited diseases with the hallmark of mutational heterogeneity.
Introduction
Inherited diseases frequently are more diverse than might be predicted from their clinical presentation. In the case of some Mendelian disorders, many different mutations within the same gene can give rise to or predispose an individual to a given disease. The presence of such immense heterogeneity underlying a clinical pathology is clearly demonstrated by Retinitis Pigmentosa (RP [MIM +180380]), a condition primarily involving photoreceptor cell loss (Farrar, Kenna, & Humphries, 2002 ). In addition, over 40 different genes have been implicated in RP. In one of these genes alone, the human rhodopsin gene (RHO [GenBank Accession No. NM_000539 .2]), over 150 mutations leading to autosomal dominant RP (adRP) have been characterised to date (Retinal Information Network Database) .
Mutational heterogeneity represents a significant barrier to the development of therapies for many inherited diseases. To address this problem in disorders such as RHOlinked RP, a mutation-independent suppression and replacement strategy has been proposed (Cashman, Binkley, & Kumar-Singh, 2005; Hauswirth & Lewin, 2000; Millington-Ward et al., 1997; O'Reilly et al., 2007) . In essence, the approach involves suppression of both mutant and wild type alleles of a target gene and concomitant provision of a replacement gene which has been sequence-modified to evade suppression (Gorbatyuk, Justilien, Liu, Hauswirth, & Lewin, 2007; Kiang et al., 2005; Palfi et al., 2006 ). In the current study RNA interference (RNAi), (Elbashir et al., 2001; Fire et al., 1998) has been used to achieve potent suppression of expression of RHO. However, other suppression agents such as ribozymes or antisense technologies could also be utilised. In parallel with suppression, a replacement gene is provided. The degeneracy of the genetic code can be employed to generate a codon-modified replacement gene in which the nucleotide sequence over the target site for suppression differs sufficiently from the wild type sequence such that transcripts from this gene are resistant to suppression but encode wild type protein. In principle, suppression and replacement circumvents the mutational heterogeneity present in RHO-linked adRP and a single therapeutic should be applicable to any adRP patient with a RHO mutation.
Codon usage has been analysed for multiple genes from many species and has been found to influence gene expression patterns (Ren et al., 2007; Shabalina, Ogurtsov, & Spiridonov, 2006) . It would be preferable when engineering codon-modified replacement genes to minimise changes in codon usage where possible. While the altered nucleotides introduced into replacement genes at wobble positions encode the same amino acids, it is possible that such base changes may influence features such as three dimensional structure or half-life of transcripts.
To explore the feasibility of suppression and replacement therapy for RHO-linked adRP, aspects of both components have been addressed in the current study. Small interfering RNAs (siRNAs) targeting RHO have been generated and RNAi-mediated suppression evaluated. Subsequently, the resistance of a codon-modified RHO replacement gene to RNAi-mediated suppression has been explored. In addition, transgenic mice expressing this replacement gene have been generated (RHO-M). Transgenic mice were mated with Rho knockout mice (RhoÀ/À), (Humphries et al., 1997) and the functional equivalence of the codon-modified RHO to rhodopsin investigated.
Materials and methods

siRNAs and RHO constructs
RHO-(NM_000539.2) targeting siRNAs, siCC, siC, siEGFP, and siNT (O'Reilly et al., 2007) , and a replacement (r) RHO cDNA, rCC-RHO, containing four and five nucleotide changes at the siCC and siC target sites, respectively, have been described ( 
RHO replacement mouse model, RHO-M
A transgenic mouse model was generated which expresses a replacement human RHO cDNA (rCC-RHO) designed to avoid suppression by siCC and siC which target codons 59-63 of RHO. Exploiting the degeneracy of the genetic code, PCR-directed mutagenesis was used to generate rCC-RHO which has altered codons 59-63 (Tables 1 and 2 and Fig. 1 ) and includes the RHO polyadenylation signal. Care was taken to maintain a similar pattern of codon usage to RHO. 3.8 kb fragment of the Rho promoter was used to express rCC-RHO and intron 9 of hypoxantine-guanine phosphoribosyltransferase (HPRT [GenBank Accession No. NM_000194]) was cloned downstream. The construct was microinjected into male pro-nuclei of fertilised eggs to generate transgenic progeny. Four founder animals, identified by Southern blotting, yielded four individual transgenic mouse lines (O'Reilly et al., 2007) . One line was evaluated in this study.
Experimental animals, immunocytochemistry, and electroretinography
One-and three-month-old wild type Rho+/+, NHR+/À RhoÀ/À expressing a normal RHO transgene (McNally et al., 1992; Olsson et al., 1992) , RHO-M+/À RhoÀ/À (O' Reilly et al., 2007) and RhoÀ/À mice (Humphries et al., 1997) were used in the study. All animals were on a 129 background. Rho immunocytochemistry, fluorescent microscopy (Kiang et al., 2005) and electroretinography (ERG) were performed as described (O'Reilly et al., 2007) . On this occasion gold wire electrodes were used rather than contact lens electrodes previously described.
Cell culture, RNA islolation and quantitative real time RT-PCR (qPCR)
CMV promoter-driven wild type RHO or rCC-RHO constructs and siCC, siC, or siNT were co-transfected in quadruplicate into HeLa cells (ATCC no. CCL-2), (Millington-Ward et al., 2004) and RNA was isolated 24 h post-transfection (Palfi et al. 2006) . RNA from retinas was isolated Numbers refer to the frequency of use of endogeneous codons versus those which have been altered in rCC-RHO. Fig. 1 . Diagrammatic representation of the construct used to generate the RHO-M mouse. Replacement RHO (rCC-RHO) incorporating the RHO cDNA with five/four altered nucleotides at wobble positions within the siC and siCC target sites, respectively, and the RHO polyadenylation signal was driven by a Rho promoter (RhoP). Intron 9 of the hypoxanthine-guanine phosphoribosyl transferase (HPRT) gene was included 3 0 of the rCC-RHO gene to facilitate transgene expression. Restriction enzyme sites and sizes are indicated. using the RNeasy Mini Kit (Qiagen Ltd. Crawley, UK). RHO mRNA expression levels were assessed by qPCR as described (O'Reilly et al., 2007) . qPCR reactions were typically performed twice in triplicate. To compare levels of endogenous mouse Rho to human RHO transgene expression qPCR with the following primer pair, which amplify both mouse and human rhodopsin mRNA, was performed:
• F: AGCAGCAGGAGTCAGCCACC; • R: CCGAAGTTGGAGCCCTGGTG.
Statistical analysis
Data sets for a given construct were pooled, averaged and standard deviation (SD) values calculated. Statistical significance of differences between control and target data sets were determined by ANOVA using least significant difference post hoc test (Data Desk 6.1, Data Descriptions Inc., New York, USA); differences with p < .05 were considered statistically significant.
Results
Previously, siRNA-mediated suppression of RHO has been explored (O'Reilly et al., 2007) . Further work up of an siRNA molecule (siCC) targeting RHO has been undertaken in the current study and both potency of RNAi-mediated suppression and resistance of a modified replacement gene (rCC-RHO, Tables 1 and 2 ) to suppression evaluated in HeLa cells. siRNAs (comprising both RHO-targeting and non-targeting controls) were co-transfected with a plasmid expressing the wild type RHO cDNA. Levels of expression achieved in cells transfected with siCC and siC were evaluated using qPCR and compared to those in cells transfected with the non-targeting control siRNA, siNT. Significant suppression of the target gene by siCC (62%; p < .01, Fig. 2A ) and siC (63%; p < .01; data not shown) was obtained at the mRNA level. RHO immunocytochemistry supported these findings as siCC suppressed RHO significantly (Fig. 2D ) while no suppression was observed with siEGFP ( Fig. 2B) or siNT (Fig. 2C) .
In addition to suppression, the possible resistance of a human replacement gene rCC-RHO which contains sequence-modifications at degenerate positions over the target site for siCC and siC (Table 1) was explored. It is notable that in generating rCC-RHO, care was taken to minimise disruption to codon usage patterns for the RHO gene (Table 2) . Where possible, synonymous codons with similar usage frequencies were employed. To explore the resistance of rCC-RHO to siCC-and siC-mediated suppression in cells, the replacement gene was expressed from either the Ubiquitine C (UBC) or the CMV promoter. siCC-mediated suppression of rCC-RHO was eliminated irrespective of the level of expression of the replacement gene from either promoter (Fig. 2A) . In contrast, siC suppressed rCC-RHO by 53% (data not shown).
Although the introduction of synonomous codons in a modified replacement gene serves to alter the nucleotide sequence whilst conserving amino acid sequence, it was important to explore the functionality of the modified rCC-RHO and encoded protein in vivo. To address this issue, a transgenic mouse RHO-M expressing rCC-RHO was generated (Fig. 1) . 3.8 kb fragment of the Rho promoter was used to drive expression of rCC-RHO. RHO-M mice were bred with RhoÀ/À mice, the latter displaying a severe form of retinal degeneration (Humphries et al., 1997) . Subsequently, doubly transgenic mice (RHO-M+/À RhoÀ/À) were evaluated by retinal histology and ERG.
Retinal histology was undertaken on RhoÀ/À, RHO-M+/À RhoÀ/À, and Rho+/+ mice at one and three months of age. In RHO-M+/À RhoÀ/À mice a single copy of the rCC-RHO transgene ( Fig. 3C and D) was found to be sufficient to compensate for the absense of Rho in RhoÀ/À mice ( Fig. 3A and B) . Notably, outer nuclear layer (ONL) thickness of RHO-M+/À RhoÀ/À mice ( Fig. 3C and Fig. 2 . Suppression of RHO in HeLa cells. A replacement RHO sequence, rCC-RHO, driven by either a CMV promoter (CMVP-rCC-RHO) or a Ubiquitin C promoter (UBCP-rCC-RHO) was generated with altered degenerate nucleotides at the siCC target site. HeLa cells were transiently co-transfected in quadruplicate with each of the above two rCC-RHO constructs and siNT, siEGFP, or siCC. Following transfection, rCC-RHO and RHO mRNA levels were evaluated by qPCR (A). Error bars represent SD values, * represents p < .01. Alternatively, suppression was evaluated using Alexa Fluor 568-labelled Rho immunocytochemistry (red). Nuclei counter-staining with DAPI (blue). B, siEGFP; C, siNT; D, siCC; and E, untransfected control. Scale bar represents 30 lm. D) was comparable to that of Rho+/+ mice ( Fig. 3E and F) . Similarly the retinal histology of RHO-M+/À RhoÀ/À mice and NHR+/À RhoÀ/À mice, the latter carrying a single copy of a wild type RHO gene and displaying a wild type phenotype (McNally et al., 1992; Olsson et al., 1992) , was found to be comparable (data not shown). Also, while the RhoÀ/À mouse shows no Rho immunolabelling and does not elaborate rod outer segments (OS, Fig. 3A and B) , RHO-M+/À Rho À/À and Rho+/+ mice show strong RHO immunolabelling in the OS (Fig. 3C and D) and outer segments are clearly visible. Note that RHO-M+/À RhoÀ/À mice display increased RHO labelling in the ONL compared to Rho+/+ mice.
In addition to retinal histology, retinal function was assessed by ERG. Notably, both the rod-isolated (Fig. 4a ) and the maximal, combined rod and cone responses (Fig. 4b) in RHO-M+/À RhoÀ/À mice were of comparable amplitudes to those from Rho+/+ and NHR+/À RhoÀ/À mice (data not shown for the latter). The rCC-RHO transgene restored the normal ERG, absent in RhoÀ/À mice in RHO-M+/À RhoÀ/À mice (Fig. 4) . Note that while a rod-derived ERG can never be detected in RhoÀ/À mice, at one month of age there is a small but measurable maximal ERG response due to cone function. Differences in ERG amplitude between 1-and 3-month-old RHO-M+/À RhoÀ/À and Rho+/+ mice represent normal variations. While clearly the results described above suggest that rCC-RHO is functionally equivalent to Rho and RHO (present in NHR animals, data not shown), it was of interest to explore levels of the rCC-RHO cDNA transgene expression (Fig. 5) . A comparison of levels of rhodopsin expression between RHO-M+/À RhoÀ/À, NHR+/À RhoÀ/À, and Rho+/+ mice using qPCR with a common primer pair, revealed that rCC-RHO in RHO-M+/À RhoÀ/À mice is expressed at approximately 75% of the level of that in NHR+/À RhoÀ/À or Rho+/+ mice (p < .01, Fig. 5 ). The level of RHO expres- Fig. 3 . Histology of RHO-M mouse retina. Ten micrometer cryosections from 1-(A, C, and E) and 3-(B, D, and F) month-old RhoÀ/À, RHO-M+/À RhoÀ/À and wild type Rho+/+ mice were labelled by Rho immunocytochemistry (Cy3; red) using RHO 4D2 antibody (Kiang et al., 2005; Li, Snyder, Olsson, & Dryja, 1996) and DAPI nuclear counterstaining (blue). Retinas of 1-and 3-month-old RHO-M (C and D) and wild type Rho+/+ animals (E and F) display normal inner and outer segments with strong Rho labelling in the latter and very similar inner and outer nuclear, and ganglion cell layers. Note that Rho labelling is more extensive in the outer nuclear layer of RHO-M mice (C and D) than in the Rho+/+ animals (E and F). In contrast, outer segments never develop in RhoÀ/À mice (A and B) and retinas lack Rho immunolabelling. Moreover, inner segments, present at one month of age (A), have degenerated completely by 3 months (B). While inner and outer nuclear layers appear nearly normal in 1-month-old RhoÀ/À mice (A), by three months, the outer nuclear layer consists of only a single row of nuclei (B). OS, rod outer segments; IS, rod inner segments; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer. Scale bar represents 50 lm. Fig. 4 . ERG analysis of RHO-M mouse. One-and three-month-old (1 and 3 m) RhoÀ/À, RHO-M+/À RhoÀ/À and wild type Rho+/+ mice were analysed by ERG. Representative rod-isolated (a) and maximal ERG responses (b) are given. Note that differences in ERG amplitudes at one and three months between Rho+/+ and RHO-M+/À RhoÀ/À are due to natural variation. Scale units are 50 ms and 500 mV. sion in NHR+/À RhoÀ/À mice and Rho expression in wild type Rho+/+ mice was found to be statistically the same. In summary, the data obtained from the study suggest that codon-modified RHO replacement genes can be engineered using the degeneracy of the genetic code to be refractory to RNAi-mediated suppression while being functionally equivalent to wild type rhodopsin.
Discussion
Understanding of the molecular pathogenesis of genetic conditions has served to highlight that many diseases are highly heterogeneous at the molecular level. Novel therapeutic approaches for such disorders, which are gene-independent, are being developed by attempting to modulate secondary features associated with the disease pathology. These include modulating apoptosis which is frequently prematurely invoked in neurodegenerative conditions including RP (Marigo, 2007) . Similarly, therapies based on provision of neurotrophic factors or anti-oxidants are being considered (Thanos & Emerich, 2005) . However, given knowledge of the underlying genetic etiologies of many conditions, it would be valuable to target therapies towards correction of the primary genetic lesion. In this regard, mutational heterogeneity inherent in even singlegene disorders such as RHO-linked adRP with over 150 different mutations represents a significant challenge.
Given this scenario, a two-component therapeutic strategy to circumvent such mutational heterogeneity, termed suppression and replacement, has been explored involving RNAi-mediated suppression used in parallel with provision of a codon-modifed replacement gene. While the principle is easy to annunciate, achieving potent suppression in conjunction with optimal levels of replacement may be challenging. Hence, elements of suppression and replacement have been explored in the current study. Potent RNAimediated suppression of RHO expression has been achieved in cell culture at both the mRNA and protein levels (Fig. 2) , as has the generation of an RNAi-resistant codon-modified RHO replacement gene, rCC-RHO (Fig. 1 ). While siCC with four nucleotide mismatches did not suppress rCC-RHO significantly, siC with five mismatches suppressed rCC-RHO by 53% (Table 1 , data not shown). This highlights the need for caution when designing therapeutic suppression and replacement constructs.
Although conservative changes were introduced into rCC-RHO to ensure that transcripts from this gene are refractory to RNAi-mediated suppression by siCC (Table 1) , it was of value to probe in depth whether a codon-modified RHO replacement cDNA was functionally equivalent to the endogenous Rho gene. RHO-M+/À mice generated for this purpose were bred onto a RhoÀ/À background and detailed histological and ERG analyses undertaken. Notably, the severe retinopathy present in RhoÀ/À mice is absent in RHO-M+/À RhoÀ/À mice due to the presence of a single copy of the rCC-RHO transgene as evaluated by retinal histology and ERG (Figs. 3 and 4) . It is of note that rCC-RHO is expressed in the ONL of adult RHO-M+/À RhoÀ/À retinas. Similarly, Rho+/+ mice express Rho in the ONL at early stages of development (typically up to 3 weeks). This indicates that rCC-RHO has not an identical transport pattern to wild type Rho in older animals, possibly due to the promoter used or a lack of intronic sequences. Evaluation of rCC-RHO transgene expression levels using qPCR indicated that the transgene was expressed at approximately 75% of the level of both Rho in wild type mice and of the RHO transgene in NHR+/À RhoÀ/À mice (Fig. 5) .
Given the mutational heterogeneity inherent in many dominantly inherited conditions, approaches such as that described in the current study will be required when attempting to correct the primary genetic defect. Indeed, suppression and replacement has been suggested as a potential therapeutic approach for other dominantly inherited conditions with the hallmark of mutational heterogeneity, for example, motor neuron disease (MIM #147450) (Xia et al., 2005) and osteogenesis imperfecta (MIM #166200), (Millington-Ward et al., 2004 ). In the current study, aspects of both the suppression and the replacement components for RHO-linked adRP therapies have been explored. Results demonstrate the feasibility both of potent RNAi-mediated suppression of RHO and generation of RNAi-resistant codon-modified replacement RHO genes which are functionally equivalent to the wild type gene. type I collagen-linked osteogenesis imperfecta, motor neuron disease), Retinal Information Network database, http://www.sph.uth.tmc.edu/Retnet/.
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